Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · August 17, 2022

Effects of Tofogliflozin and Glimepiride on NAFLD in People With Type 2 Diabetes

Diabetes Care


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes Care
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial
Diabetes Care 2022 Jul 27;[EPub Ahead of Print], Y Takeshita, M Honda, K Harada, Y Kita, N Takata, H Tsujiguchi, T Tanaka, H Goto, Y Nakano, N Iida, K Arai, T Yamashita, E Mizukoshi, H Nakamura, S Kaneko, T Takamura

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading